<DOC>
	<DOCNO>NCT02249702</DOCNO>
	<brief_summary>The management patient uterine leiomyosarcomas pose many difficulty . Despite 60 % woman present disease limit uterus , cure rate range 20 60 % . Patients metastatic disease diagnosis recur initial treatment dismal prognosis , except subset select patient completely resectable disease , median survival less one year . Treatment option recurrent/metastatic uterine leiomyosarcoma limit . The active drug doxorubicin ± ifosfamide gemcitabine + docetaxel ( GD ) response rate 25-55 % 27-53 % , respectively . Both regimens increasingly use last year also adjuvant set . For relapsed patient drug test single agent negligible activity observe . Trabectedin ( Yondelis® -T ) marine-derived cytotoxic approve EMEA . It indicate treatment patient advance soft tissue sarcoma , failure anthracyclines ifosfamide unsuitable receive agent . Among STS , activity mainly detect synovial sarcoma , liposarcoma leiomyosarcoma . Although response rate exceed 10 % , T demonstrate provide disease control , progression arrest rate exceed 50 % progression-free survival rate exceed 20 % 6 month . So far phase II study test activity T uterine leiomyosarcoma specifically . This study aim evaluate activity T ( arm A ) advance uterine leiomyosarcoma , GD ( arm B ) internal control In parallel translational study perform identify factor predictive activity T specific histotype .</brief_summary>
	<brief_title>Activity Trabectedin Gemcitabine + Docetaxel Uterine Leiomyosarcoma</brief_title>
	<detailed_description />
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>1 . Histologically proven uterine leiomyosarcoma . 2 . Persistent locally relapse and/or metastatic disease . 3 . At least one previous systemic treatment anthracycline ± ifosfamide gemcitabine ± docetaxel . 4 . Measurable disease , define RECIST criterion . 5 . ECOG PS &lt; =2 . 6 . Age &gt; = 18 year . 7 . A minimum 3 week since prior tumor direct therapy 8 . Recovery toxic effect prior therapy NCI CTC Grade 1 low . 9 . Adequate haematological function . 10 . Adequate renal function . 11 . Adequate liver function . 12 . Signed informed consent . 1 . Prior exposure Trabectedin . 2 . Peripheral neuropathy , Grade 2 high . 3 . History malignancy ( except basal cell carcinoma cervical carcinoma situ , adequately treat ) , unless remission 5 year judge negligible potential relapse . 4 . Known CNS metastasis . 5 . Active viral hepatitis chronic liver disease . 6 . Unstable cardiac condition , include congestive heart failure angina pectoris , myocardial infarction within one year enrolment , uncontrolled arterial hypertension arrhythmia . 7 . Active major infection . 8 . Other serious concomitant illness</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>trabectedin</keyword>
	<keyword>uterine leiomyosarcoma</keyword>
</DOC>